Medivir AB News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

19.06.17	Medivir Appoints John Öhd as Chief Medical Officer (PR Newswire)
09.06.17	Medivir - Enrolment Completed in the MIV-711 Osteoarthritis Extension Study and Data Monitoring Committee Recommendation to "Go Ahead" (PR Newswire)
01.06.17	Global Online Apparel Retailing Market 2017-2021 - Research and Markets (PR Newswire)
30.05.17	Medivir's CFO Will Leave his Position - Successor Recruitment Underway (PR Newswire)
03.05.17	Resolutions at the Annual General Meeting in Medivir on 3 May 2017 (PR Newswire)
24.04.17	Update on the Development of Simeprevir as Part of the Triple Combination With AL-335 and Odalasvir (JNJ-4178) (PR Newswire)
07.04.17	Medivir Announces Positive Data From the Phase II Study of Remetinostat in Patients With Early-stage Cutaneous T-cell Lymphoma (PR Newswire)
06.04.17	Medivir - New Data on MIV-818 Will be Presented at EASL's International Liver Congress™ 2017 (PR Newswire)
04.04.17	Annual Report 2016 - Medivir (PR Newswire)
03.04.17	Notice of Annual General Meeting of Medivir AB (publ) (PR Newswire)
31.03.17	Number of Shares and Votes in Medivir (PR Newswire)
16.03.17	Medivir Completes Transition of Commercial Products to Fully Focus on Research and Development (PR Newswire)
03.03.17	Presentation of the Result of Medivir's Voluntary Redemption Programme (PR Newswire)
17.02.17	Executive Management Team Members Increase Their Holdings in Medivir (PR Newswire)
09.02.17	Christine Lind new CEO of Medivir AB Effective 1 April 2017 (PR Newswire)
06.02.17	Medivir Capital Markets Meeting on 23 February 2017 (PR Newswire)
01.02.17	MIV-711 Osteoarthritis Trial: Successful Fourth Independent Review of Safety Data Enables Trial Continuation Without any Modifications (PR Newswire)
10.01.17	Notice of Extraordinary General Meeting of Medivir AB (publ) (PR Newswire)
09.01.17	Medivir - Invitation to Conference Call and Webcast (PR Newswire)
29.12.16	Medivir Completes Previously Announced Oncology Programs Acquisition (PR Newswire)
15.12.16	Medivir Completes the Divestment of BioPhausia - a Transfer of Approx. SEK 870m to the Shareholders Through a Share Redemption Offer will be Proposed (PR Newswire)
14.12.16	Medivir's fusion inhibitor for the treatment of Respiratory Syncytial Virus infection, MIV-323, enters non-clinical development (PR Newswire)
08.12.16	MIV-711 Osteoarthritis Trial: Successful Third Independent Review of Safety Data and Trial Continues Without any Modifications (PR Newswire)
08.12.16	Medivir: MIV-711 Osteoarthritis Trial: Successful Third Independent Review of Safety Data and Trial Continues without Any Modifications (Businesswire)
08.12.16	Medivir: MIV-711 Osteoarthritis Trial: Successful Third Independent Review of Safety Data and Trial Continues without Any Modifications (Businesswire)
28.11.16	Medivir announces that Janssen has initiated an open-label phase IIb study of the 3DAA combination of simeprevir, odalasvir and AL-335 (JNJ-4178) (Businesswire)
10.11.16	Medivir AB – Interim Report, January – September 2016 (Businesswire)
03.11.16	Medivir: Invitation to Conference Call and Webcast Today 3 November, at 14.30 CET (Businesswire)
02.11.16	Medivir Strengthens Its Clinical Pipeline by Entering into Agreement to Acquire a Portfolio of Clinical Stage Oncology Programs (Businesswire)
01.11.16	Medivir: Medivir’s Nucleotide Polymerase Inhibitor for the Treatment of Liver Cancer, MIV-818, Enters Non-Clinical Development (Businesswire)
01.11.16	Medivir Divests Its Pharmaceutical Company BioPhausia (Nordic Brands) to Karo Pharma (Businesswire)
27.10.16	Medivir: MIV-711 Osteoarthritis Program: Enrollment in the Phase IIa Study is Complete and Independent Safety Review Committee Again Recommends Go Ahead (Businesswire)
10.10.16	Medivir Focuses Exclusively on Oncology and Reorganizes to Significantly Reduce the Cost Structure (Businesswire)
23.09.16	Medivir: Updated Interim Phase IIa Data Demonstrate That the Combination of Simeprevir, Odalasvir and AL-335 Has a High Level of Efficacy in HCV Patients (Businesswire)
23.09.16	Medivir: MIV-711 Osteoarthritis Trial: Recommendation to Go Ahead Based on Independent Review of Safety Data, and First Patient Enrolled in Extension Study (Businesswire)
09.09.16	Medivir: Interim Results from Phase IIa Trial Evaluating Triple Combination Including Simeprevir Demonstrates High Level of Efficacy in HCV Patients (Businesswire)
31.08.16	Medivir Proceeds with a Separation of the Company’s Operations (Businesswire)
17.08.16	Medivir Licenses Rights to MIV-802 to Trek Therapeutics (Businesswire)
17.08.16	Medivir AB – Interim Report, January – June 2016 (Businesswire)
11.08.16	Medivir: New Interim Phase IIa Data on Simeprevir in Combination with Other DAAs Will Be Presented at the Upcoming EASL AASLD Special Conference (Businesswire)
15.06.16	Medivir Investigates Possible Corporate Split and Separate Listing of Commercial Operations (Businesswire)
11.05.16	Medivir Announces That Janssen Decided to Start a Phase IIb Study of Combinations of Simeprevir, Odalasvir and AL-335 for the Treatment of Hepatitis C (Businesswire)
03.05.16	Resolutions at the Annual General Meeting in Medivir on 3 May 2016 (Businesswire)
28.04.16	Medivir AB – Interim Report, January – March 2016 (Businesswire)
19.04.16	Medivir: OLYSIO® sales during the first quarter 2016 (Businesswire)
11.04.16	Medivir: New Data for Simeprevir Will Be Presented at Easl's International Liver Congress 2016 (Businesswire)
06.04.16	Medivir: Annual Report 2015 (Businesswire)
31.03.16	Notice of Annual General Meeting of Medivir AB (publ) (Businesswire)
03.03.16	Medivir’s Nomination Committee proposes new Board of Directors ahead of 2016 AGM (Businesswire)
18.02.16	Medivir AB – Financial Statement, January – December 2015 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swisscom	527.00	2.33 %	K V
Holcim	95.34	1.21 %	K V
UBS Group	30.42	0.86 %	K V
Roche Hldg G	289.00	0.45 %	K V
Swiss Re	141.65	0.35 %	K V
Givaudan	3’850.00	-1.48 %	K V
Lonza Grp	603.80	-1.50 %	K V
Alcon	82.30	-1.53 %	K V
Geberit	508.00	-1.74 %	K V
Part Grp Hldg	1’386.00	-2.26 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Medivir AB

Aktien Top/Flop

Meistgelesene Nachrichten